Evidence map›Paper›PMID 42365227›Full record

ArticleCellular & molecular biology letters2026

Cannabidiol alleviates traumatic brain injury-induced neuronal damage and cognitive deficits by inhibiting ferroptosis via the TRPV1/MCU/PI3K/Akt pathway.

Yejia Xu, Xiong Li, Zhiya Gu, Xuehua Chen, Yang Zhao, Bowen Jia, Yumeng Wu, Rui Wan, Qianqian Li, Tao Wang and 1 more

Abstract read
In one paragraph

Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yejia Xu *Department of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China.
Xiong Li *Department of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China.
Zhiya Gu *Jiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, School of Basic Medical Sciences, Soochow University, Suzhou, 215123, China.
Xuehua ChenDepartment of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China.
Yang ZhaoDepartment of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China.
Bowen JiaJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, School of Basic Medical Sciences, Soochow University, Suzhou, 215123, China.
Yumeng WuDepartment of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China.
Rui WanDepartment of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China.
Qianqian LiDepartment of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China. bzliqian@126.com.
Tao WangJiangsu Key Laboratory of Drug Discovery and Translational Research for Brain Diseases, School of Basic Medical Sciences, Soochow University, Suzhou, 215123, China. taowang@suda.edu.cn.
Chengliang LuoDepartment of Forensic Medicine, School of Forensic Medicine, National Health Commission Key Laboratory of Drug Addiction Medicine, Kunming Medical University, 650500, Kunming, China. luochengliang@kmmu.edu.cn.

Funding

National Natural Science Foundation of China 82460256, 82271409National Training Program of Innovation and Entrepreneurship for Undergraduate 202510678024Yunnan Provincial Key Project for Basic Research Program 202501AS070020
6 · The paper itself

Abstract

backgroundTraumatic brain injury (TBI) is a common surgical traumatic condition that poses a significant threat to human health and working capacity. However, effective treatments to improve its prognosis remain limited. Cannabidiol (CBD), a naturally occurring compound extracted from the cannabis plant, exhibits multiple pharmacological effects through diverse molecular targets. To date, the role and underlying molecular mechanisms of CBD in the context of TBI have not been fully elucidated. In this study, we investigated the specific effects of CBD following TBI and explored its underlying mechanisms.

methodsAn in vitro ferroptosis model was established using HT-22 cells, and an in vivo TBI model was established in mice. Techniques such as Western blotting, immunofluorescence staining, and behavioral analysis were employed to evaluate the effects of CBD on ferroptosis, pathological changes, and neurological function after TBI, as well as to explore the associated molecular mechanisms.

resultsCBD significantly alleviated ferroptosis, neuronal injury, and cognitive dysfunction following TBI in vitro and in vivo. Further investigation revealed that CBD mitigated mitochondrial dysfunction by reducing Ca

conclusionsCBD inhibits ferroptosis, at least in part, via the TRPV1/MCU/PI3K/Akt signaling pathway, thereby alleviating TBI-induced neuronal damage and cognitive deficits. In addition, these findings indicate that CBD exhibits a potent anti-ferroptotic effect and may serve as a promising therapeutic agent for TBI.

Indexed as

Brain Injuries, TraumaticCannabidiolCognitive DysfunctionFerroptosisNeuronsSignal TransductionAnimalsCalcium ChannelsCell LineHumansMaleMiceMice, Inbred C57BLPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTRPV Cation ChannelsCalcium ChannelsCannabidiolPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTRPV1 protein, mouseTRPV Cation ChannelsCannabidiolCognitive deficitsFerroptosisMitochondrial calcium uniporterTraumatic brain injury

Identifiers

PMID42365227
PMCPMC13591781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.